Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant for Alzheimer's disease prevention
ISRCTN63918057Phase 2Recruiting
- Sponsor
- Douglas Mental Health University Institute
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Alzheimer's disease (AD) comparing Daridorexant with Placebo (2 arms). Primary endpoint: Biological progression by plasma p-tau217/np-tau217 ratio. Started Oct 2025; status: recruiting.
02
Drugs
daridorexant
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ISRCTN63918057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63918057.